If further confirmed in vivo, triggering mRNA instability by inducing TTP and reducing HuR may be approached as a targeted therapy modality, not only in invasive breast cancer but also in other cancer types and diseases, such as auto-immune and chronic inflammatory states. Here, ELAVL1 is linked to invasive breast carcinoma.